[Treatment of severe open cavitary pulmonary tuberculosis with a combination of rifampicin and isoprodian (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage* / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000627:therapeutic use; D007539:Isonicotinic Acids / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011515:Prothionamide / Q000008:administration & dosage* / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D004338:Drug Combinations; D007539:Isonicotinic Acids; D011515:Prothionamide; D003622:Dapsone; D007538:Isoniazid; D012293:Rifampin
Erste Erfahrungen mit der Kombination Isoprodian + Rifampicin in der Behandlung schwerer, offener, kavernöser Lungentuberkulose